Crystal Pharmatech's 2nd Workshop on Polymorphism and Crystallization Closed Successfully
Crystal Pharmatech Co., Ltd successfully concluded a two-day workshop on polymorphism and crystallization of pharmaceuticals at Zhangjiang Biotech and Pharmaceutical Base (Zhangjiang Drug Valley) in Shanghai, China on September 15th and 16th.
- (1888PressRelease) October 09, 2011 - This is the 2nd training offered by Crystal Pharmatech to help pharmaceutical companies in China realize the importance of polymorphism and improve drug R&D capability in the field of solid state research in drug development. The workshop attracted over 200 scientists, managers, and state officials representing more than 80 China based pharmaceutical companies and research institutes.
To establish an open, harmonious platform for in-depth discussion and communication in the polymorphism and solid state research field, Crystal Pharmatech invited experts from other esteemed organizations in addition to their internal experts to give presentations and participate in panel discussions. These organizations include: National Institutes for Food and Drug Control, Shanghai/Zhejiang/Suzhou Institutes for Food and Drug Control, The State Research Center of Industrialization for Crystallization Technology, Sun Yat-Sen University, China Pharmaceutical University, etc. Through organizing such workshops Crystal Pharmatech intends to foster open discussions among industry, academia and government agencies to bring solid state research of pharmaceuticals to a new level and help China drug companies to improve drug quality by focusing more on this field.
The workshop program was specifically designed to suit the participants' needs and illuminate the impact of solid state properties in pharmaceutical development. Key topics include: 1) Fundamental Knowledge of Polymorphism; 2) Impact of Crystalline Forms on Drug Quality Control; 3) Hydrates in Drug Development; 4) Process Development and Optimization thru Crystallization; 5) Approaches to Chiral Resolution Thru Crystallization; 6) Polymorph Studies in Formulation Development; 7) Co-crystals and Amorphous Phase; 8) Solid-State NMR for Pharmaceutical Characterization. Crystal Pharmatech's CSO, Dr. Yanfeng Zhang, also presented over 20 selected case studies covering all drug development stages in solid state chemistry. These examples highlighted Crystal Pharmatech's dedicated research over the past year and demonstrated from real experiences on how to approach challenging problems on polymorphism and crystallization issues. "The case studies were eye-opening. I see similar issues everyday at my company but had little idea how a solid understanding of the solid state can improve my processes and eventually the drug quality", said Ms. Feng from Shanghai Hearem Pharmaceutical. "This training was very informative and helpful. I'm sure to check Crystal Pharmatech's training website frequently, anticipating the next session", states Mr. Zhao, group leader from Esteve Huayi Company.
"These positive responses for our workshop are very encouraging" explains Dr. Alex M. Chen, CEO of Crystal Pharmatech Co., Ltd. "More and more Chinese companies start to realize the importance of polymorphism and crystallization in drug development and manufacturing. China's R&D capability in this field is rather lacking compared to big US and Europe drug companies. We will continue to organize this kind of workshops and help advance China's capability in this field. These are incredibly exciting times in China and we are honored to be a part of it." Crystal Pharmatech also plans to establish scholarships in selected colleges and universities that encourage outstanding students to get trained and work in solid state research of pharmaceuticals. It truly believes that collaborative efforts between industry, academia and government agencies are essential to advance China's capability in solid state research of pharmaceuticals to a new level.
Crystal Pharmatech is a technology-driven CRO that focuses on specialized fields of solid state information and processing for active pharmaceutical ingredients and formulations. It helps its clients to discover and select the optimal solid phase for drug development, design and develop scalable and efficient API crystallization processes to ensure desired quality attributes, and aid in developing the best formulations based on sound scientific understanding. It provides its clients a complete and satisfactory solution to the problem they face instead of merely running experiments and collecting data. Since founded in 2010, Crystal Pharmatech has already built strong business relationship with more than 50 global pharmaceutical companies. By providing high quality service with fast turnaround at cost-effective pricing, Crystal Pharmatech is becoming an ideal partner in the field of solid state research for many pharmaceutical companies.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam